65,114 Shares of Tempus AI, Inc. $TEM Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 65,114 shares of the company’s stock, valued at approximately $5,333,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC increased its holdings in Tempus AI by 5.9% in the third quarter. ProShare Advisors LLC now owns 6,500 shares of the company’s stock worth $532,000 after purchasing an additional 360 shares in the last quarter. Vise Technologies Inc. bought a new stake in Tempus AI in the third quarter worth approximately $235,000. International Assets Investment Management LLC lifted its stake in Tempus AI by 3,027.6% in the third quarter. International Assets Investment Management LLC now owns 104,555 shares of the company’s stock valued at $8,563,000 after buying an additional 101,212 shares during the period. Partners Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at approximately $241,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Tempus AI by 15.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,002 shares of the company’s stock worth $2,643,000 after buying an additional 4,227 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. HC Wainwright lifted their price objective on shares of Tempus AI from $68.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group initiated coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $56.00 to $76.00 in a research note on Tuesday, September 1st. Finally, Jefferies Financial Group raised shares of Tempus AI from an “underperform” rating to a “hold” rating and increased their target price for the stock from $35.00 to $70.00 in a research note on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $79.37.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while HC Wainwright and Robert W. Baird were also reported to see strong potential appreciation. These recommendations may support investor confidence. Cantor Fitzgerald maintains Buy rating HC Wainwright forecast Baird forecast
• Positive Sentiment: Recent results were stronger than expected: Tempus reported quarterly revenue of $411.5 million, up 23.1% year over year, and earnings per share of $0.07 versus analysts’ forecast for a loss. The beat provides a favorable business-performance backdrop. Tempus AI earnings beat
• Negative Sentiment: CEO Ryan Fukushima sold 80 shares and director David Epstein sold 370 shares at $74.29. Both trades were executed under pre-arranged Rule 10b5-1 plans, and the small sales leave their substantial holdings largely intact, tempering the potential concern. Director stock sale disclosure

Tempus AI Stock Performance

Shares of TEM opened at $70.43 on Friday. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 3.16. The stock has a 50-day moving average of $71.21 and a 200-day moving average of $57.20. The company has a market cap of $12.71 billion, a PE ratio of -66.44 and a beta of 3.61. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $89.09.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The business had revenue of $411.54 million during the quarter, compared to analyst estimates of $409.39 million. During the same period in the previous year, the company posted ($0.46) EPS. The firm’s revenue was up 23.1% compared to the same quarter last year. On average, equities research analysts predict that Tempus AI, Inc. will post -1.45 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In other Tempus AI news, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the completion of the sale, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. This represents a 13.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,237,227 shares of company stock worth $85,388,983 in the last three months. Insiders own 24.26% of the company’s stock.

Tempus AI Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.